TP53 and melanoma: These evidences were partially confirmed in melanoma patient-derived xenograft (PDX) model, where administration of Nutlin-3, an antagonists of the p53-inhibitor MDM2, was effective in stabilizing p53, restoring p21 expression and counteracting resistance to CDK-i (56, 85).